Archives
-
Q-VD(OMe)-OPh: Designing Better Apoptosis Evidence
2026-08-12
A translational guide to using Q-VD(OMe)-OPh as a mechanistic control in complex cell-death studies, with lessons from cetuximab-resistant colorectal cancer research and applications in cancer differentiation and neuroprotection.
-
WEHI-539: Practical BCL-XL Apoptosis Workflows
2026-08-11
Learn how WEHI-539, SKU A3935, can improve the interpretation and reproducibility of BCL-XL-dependent apoptosis experiments. This scenario-driven guide covers assay design, handling constraints, mechanistic controls, data interpretation, and vendor-selection considerations.
-
Naftifine HCl: A Cross-Scale Assay Framework
2026-08-11
Naftifine HCl is an allylamine antifungal agent whose sterol-targeting mechanism supports rigorous, multi-readout fungal assays. This article applies the evidence architecture of a landmark WNT5a/GSK3/β-catenin study to improve assay design while clearly separating fungal pharmacology from muscle-cell biology.
-
Pseudo-UTP: From IVT Chemistry to Translational Assays
2026-08-10
Pseudo-UTP enables mRNA synthesis with pseudouridine modification, but its value extends beyond RNA stability enhancement. This article connects nucleotide selection, LNP delivery, and disease-relevant assay design using insights from a targeted mRNA study in ischemic stroke.
-
Calpain Inhibitor I, ALLN: Practical Lab Guide
2026-08-07
Calpain Inhibitor I, ALLN (SKU A2602) is a DMSO-soluble cysteine-protease inhibitor for workflows examining calpain and cathepsin contributions to apoptosis, inflammation, and ischemia-reperfusion injury. It should be used with vehicle controls and orthogonal readouts, and is not intended for diagnostic, therapeutic, or single-protease-specific applications.
-
AZD0156 and ATM Inhibition: Precision Tools for DNA Repair R
2026-08-02
Explore the scientific advances and practical implications of using AZD0156, a potent ATM kinase inhibitor, for dissecting DNA double-strand break repair and checkpoint modulation. This article delivers a unique, evidence-driven perspective on integrating ATM inhibition into cancer therapy research and experimental design.
-
Rucaparib (AG-014699): Revolutionizing DNA Damage Response A
2026-08-01
Rucaparib (AG-014699) opens new horizons in DNA damage response research, offering precise radiosensitization in PTEN-deficient and ETS fusion-positive cancer models. This guide dives deep into advanced protocols, troubleshooting, and the transformative fallout of Pol II degradation findings for experimental design.
-
Rotenone as a Mitochondrial Complex I Inhibitor: Advanced Wo
2026-07-31
Rotenone is the gold-standard mitochondrial Complex I inhibitor, enabling precise modeling of mitochondrial dysfunction, apoptosis, and autophagy in both cellular and in vivo studies. Discover optimized protocols, troubleshooting strategies, and recent breakthroughs that enhance the reproducibility and translational value of rotenone-based disease models.
-
KX2-391 Dihydrochloride: Precision Src Inhibition in Melanom
2026-07-30
Explore the dual mechanism of KX2-391 dihydrochloride as a precise Src kinase and tubulin inhibitor in cancer research. This article uniquely dissects its translational value in conjunctival melanoma and antiviral studies, offering advanced protocol insights and actionable comparisons.
-
Chlamydial OmpA Vesicles Block Mitochondrial Apoptosis in Ho
2026-07-28
This study reveals that Chlamydia trachomatis delivers its outer membrane protein OmpA to host mitochondria via bacterial membrane vesicles, where OmpA directly inhibits apoptotic signaling by interacting with BCL-2 family effectors. These mechanistic findings provide new insight into how intracellular pathogens actively evade host cell death, with broad implications for apoptosis research.
-
Mitochondrial Defects Drive AML Sensitivity to Mitotoxic Dru
2026-07-27
This study reveals that acute myeloid leukemia (AML) cells possess unique mitochondrial metabolic vulnerabilities, making them highly sensitive to mitocan drugs—agents targeting mitochondrial function. By combining mitochondrial uncouplers with glycolytic inhibitors, the research demonstrates selective anti-leukemic effects with minimal toxicity to healthy blood cells, offering a promising therapeutic direction.
-
3-Bromopyruvate and Cetuximab: Inducing Ferroptosis to Overc
2026-07-26
This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab overcomes resistance in colorectal cancer cells by inducing autophagy-dependent ferroptosis and apoptosis. The mechanistic insights into FOXO3a pathway activation provide a foundation for targeting resistant cancers and optimizing cell death assays.
-
Isosteroidal Alkaloids from Fritillaria Suppress Inflammatio
2026-07-25
This study identifies four isosteroidal alkaloids from Fritillaria that significantly suppress lipopolysaccharide-induced inflammation both in vitro and in vivo by targeting MyD88- and TRIF-dependent signaling. Detailed mechanistic analyses, including cell proliferation and cytotoxicity assessment with tetrazolium salt assays, reveal their potential for modulating inflammatory pathways and protecting against acute lung injury.
-
Verapamil ((±)-Verapamil): Applied Workflows in Hypoxia Mode
2026-07-23
Verapamil ((±)-Verapamil) is transforming hypoxia-inflammation research by enabling targeted modulation of the TXNIP/NLRP3 axis in urothelial cells. This guide breaks down experimental workflows, troubleshooting tips, and the unique mechanistic insights that set this calcium channel blocker apart for advanced in vitro studies.
-
Ouabain in Translational Research: Beyond the Na+/K+-ATPase
2026-07-20
Explore ouabain’s role as a selective Na+/K+-ATPase inhibitor in translational research. This article delivers advanced insight into its mechanistic impact, assay optimization, and its pivotal value for modeling complex cardiac and cellular pathophysiology.